On February 6, 2026, Ernexa Therapeutics Inc. announced a public offering of 19 million shares of common stock at $0.50 each, raising approximately $10.5 million before expenses. The shares and warrants will trade on Nasdaq and will be used to advance the company’s development programs and for general corporate purposes.